CHMP foreslog en ændring af afsnit 4. 4 i produktresuméet for at mindske risikoen for tilbageholdelse af behandling hos patienter med okulær rosacea.
The CHMP proposed the amendment of section 4.4 of the SPC, in order to minimise the risk for withholding treatment from patients with ocular rosacea.